Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
about
Molecular biomarkers to guide precision medicine in localized prostate cancer.Genomic tests to guide prostate cancer management following diagnosis.PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles.ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature
P2860
Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Loss of PTEN expression in ERG ...... e after radical prostatectomy.
@en
Loss of PTEN expression in ERG ...... e after radical prostatectomy.
@nl
type
label
Loss of PTEN expression in ERG ...... e after radical prostatectomy.
@en
Loss of PTEN expression in ERG ...... e after radical prostatectomy.
@nl
prefLabel
Loss of PTEN expression in ERG ...... e after radical prostatectomy.
@en
Loss of PTEN expression in ERG ...... e after radical prostatectomy.
@nl
P2093
P2860
P50
P1433
P1476
Loss of PTEN expression in ERG ...... e after radical prostatectomy.
@en
P2093
Andrew Erickson
Anna Bützow
Hanna Vasarainen
Heikki Seikkula
Irena Saarinen
Kanerva Lahdensuo
Mikael Lundin
Pekka Taimen
Peter J Boström
Stig Nordling
P2860
P2888
P304
P356
10.1038/MODPATHOL.2016.154
P577
2016-08-26T00:00:00Z